Kynurenic acid and zaprinast diminished CXCL17-evoked pain-related behaviour and enhanced morphine analgesia in a mouse neuropathic pain model

Pharmacol Rep. 2019 Feb;71(1):139-148. doi: 10.1016/j.pharep.2018.10.002. Epub 2018 Oct 6.

Abstract

Background: The G protein-coupled receptor 35 (GPR35), is considered important for nociceptive transmission, as suggested by accumulating evidence. This receptor was discovered in 1998; however, a lack of pharmacological tools prevented a complete understanding of its function and how to exploit it therapeutically. We studied the influence of CXCL17, kynurenic acid and zaprinast on nociceptive transmission in naïve and neuropathic mice. Additionally, we investigated the influence of kynurenic acid and zaprinast on morphine effectiveness in neuropathic pain.

Methods: The chronic constriction injury (CCI) of the sciatic nerve in Swiss mice was performed. The CXCL17, kynurenic acid, zaprinast and morphine were injected intrathecally into naive and CCI-exposed mice at day 14. To evaluate tactile and thermal hypersensitivity, the von Frey and cold plate tests were used, respectively.

Results: Our results have shown, for the first time, that administration of CXCL17 in naïve mice induced strong pain-related behaviours, as measured by von Frey and cold plate tests. Moreover, we demonstrated that kynurenic acid and zaprinast diminished CXCL17-evoked pain-related behaviours in both tests. Kynurenic acid and zaprinast reduced thermal and tactile hypersensitivity developed by sciatic nerve injury and strongly enhanced the effectiveness of morphine in neuropathy.

Conclusions: Our study highlights the importance of GPR35 as a receptor involved in neuropathic pain development. Therefore, these results suggest that the modulation of GPR35 could become a potential strategy for the treatment of neuropathic pain.

Keywords: CXCL17; Kynurenic acid; Morphine; Zaprinast.

MeSH terms

  • Analgesics / administration & dosage
  • Analgesics / pharmacology*
  • Analgesics, Opioid / administration & dosage
  • Analgesics, Opioid / pharmacology*
  • Animals
  • Behavior, Animal / drug effects*
  • Chemokines, CXC / administration & dosage
  • Chemokines, CXC / toxicity*
  • Disease Models, Animal
  • Injections, Spinal
  • Kynurenic Acid / administration & dosage
  • Kynurenic Acid / pharmacology*
  • Male
  • Mice
  • Morphine / administration & dosage
  • Morphine / pharmacology*
  • Pain Perception / drug effects*
  • Pain Threshold / drug effects*
  • Purinones / administration & dosage
  • Purinones / pharmacology*
  • Receptors, G-Protein-Coupled / drug effects
  • Receptors, G-Protein-Coupled / metabolism
  • Sciatica / chemically induced
  • Sciatica / drug therapy*
  • Sciatica / physiopathology
  • Sciatica / psychology
  • Spinal Cord / drug effects*
  • Spinal Cord / metabolism
  • Spinal Cord / physiopathology

Substances

  • Analgesics
  • Analgesics, Opioid
  • Chemokines, CXC
  • GPR35 protein, mouse
  • Purinones
  • Receptors, G-Protein-Coupled
  • Morphine
  • zaprinast
  • Kynurenic Acid